PREDICTORS OF PREGNANCY OUTCOMES IN SLE AND APS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究调查了受试者产后三个月内的妊娠结局。将在受试者怀孕期间和产后期间进行体检和尿液和血液测试，并就受试者的怀孕情况与受试者进行面谈。还将获得完整的病史。这些信息将被用来更好地了解系统性红斑狼疮(SLE)或抗磷脂综合征(APS)女性的妊娠成功与低补体缺乏症之间的关系。这项研究将试图衡量以下结果/事件：1)妊娠12周后发生的不明原因的胎儿死亡，2)出院前因早产并发症而导致的新生儿死亡，3)因妊娠高血压、先兆子痫或胎盘功能不全而在36周前早产，以及4)宫内生长受限(IUGR)，其定义为新生儿出生体重低于胎龄的第10个百分位数。此外，这项研究还将试图确定APL抗体患者的循环和胎盘中是否会检测到经典、替代和末端补体途径的激活，并与不良妊娠结局相关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study examined pregnancy outcomes over the course of the subject's pregnancy through three months postpartum. Physical examinations and urine and blood tests will be conducted during the subject's pregnancy and during the postpartum time period, as well as interviews with the subject regarding her pregnancy. A complete medical history will also be obtained. This information will be used to gain a better understanding of the relationship between pregnancy success and low complement deficiencies in women with Systemic Lupus Erythematosus (SLE) or Antiphospholipid syndrome (APS). The study will seek to measure the following outcomes/events: 1) unexplained fetal death occurring 12 weeks after gestation, 2) neonatal death prior to hospital discharge and due to complications of prematurity, 3) indicated preterm delivery prior to 36 weeks' gestation because of gestational hypertension, pre-eclampsia or placental insufficiency, and 4) intrauterine growth restriction (IUGR) which is defined as neonatal birth weight less than the 10th percentile for gestational age. Further, the study will also seek to identify whether classical, alternative, and terminal complement pathway activation will be detected in the circulation and placenta of patients with aPL antibodies, and associated with poor pregnancy outcomes.